We unite science, technology and talent to get ahead of disease together.
Purpose, strategy and culture
Getting ahead of disease is one of the greatest, most inspiring challenges there is on the planet. By pursuing this purpose together, we have the scale and expertise to positively impact the health of 2.5 billion people in the next 10 years. In doing so, we will deliver stronger and more sustainable growth as a company where people can thrive.Explore our Purpose, strategy and culture
At a glance
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs.Explore GSK in the US
Learn about our US businesses
Leading the way to reimagine improved ways of engaging with people with cancer
Helping patients breathe better by redefining treatment for COPD and asthma
Transforming immuno-inflammatory clinical practice and improving patient outcomes
Making an impact for society by tackling some of the world’s most devastating diseases
ViiV Healthcare is fully dedicated to leaving no person living with HIV behind
View our policy positions
We have policies in place across GSK to ensure we meet the high standards we set ourselves as a company, and those that are expected of us externally.
Learn more about our views and our practices across a range of issues that are important to GSK, our patients and our stakeholders.
Latest press releases
- US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
- GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
- Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone